Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kentaro Kumazawa
Excision Repair Cross-Complementing Group-1 (ERCC1) Induction Kinetics and Polymorphism Are Markers of Inferior Outcome in Patients With Colorectal Cancer Treated With Oxaliplatin
Oncotarget
Oncology
Related publications
ERCC1 (Excision Repair Complementing Defective Repair in Chinese Hamster)
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer Research
Oncology
Genetics
Hematology
Association Between Excision Repair Cross-Complementation Group 1 Polymorphism and Clinical Outcome of Platinum-Based Chemotherapy in Patients With Epithelial Ovarian Cancer
Experimental & Molecular Medicine
Association Studies of Excision Repair Cross-Complementation Group 1 (ERCC1) Haplotypes With Lung and Head and Neck Cancer Risk in a Caucasian Population
Cancer Epidemiology
Cancer Research
Epidemiology
Oncology
Excision Repair Cross-Complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer
Clinical Cancer Research
Cancer Research
Oncology
The Prognostic and Predictive Value of Excision Repair Cross-Complementation Group 1 (ERCC1) Protein in 1288 Patients With Head and Neck Squamous Cell Carcinoma Treated With Platinum-Based Therapy: A Meta-Analysis
European Archives of Oto-Rhino-Laryngology
Medicine
Otorhinolaryngology
Correlation of ERCC1 Expression in Peripheral Blood Lymphocytes With Outcomes of Patients With Gastric Cancer Treated With Oxaliplatin-Based Adjuvant Chemotherapy
Genetics and Molecular Research
Medicine
Genetics
Molecular Biology
Let-7 miRNA-binding Site Polymorphism in the KRAS 3′UTR; Colorectal Cancer Screening Population Prevalence and Influence on Clinical Outcome in Patients With Metastatic Colorectal Cancer Treated With 5-Fluorouracil and Oxaliplatin +/− Cetuximab
BMC Cancer
Cancer Research
Oncology
Genetics
miR‑138‑5p Modulates the Expression of Excision Repair Cross‑complementing Proteins ERCC1 and ERCC4, and Regulates the Sensitivity of Gastric Cancer Cells to Cisplatin
Oncology Reports
Medicine
Cancer Research
Oncology
AB153. Down-Regulated Expression of Excision of Repair Cross-Complementing Gene 1 Reduces Resistance to Hydroxycamptothecine in Bladder Cancer
Translational Andrology and Urology
Reproductive Medicine
Urology
